ROSSI, FRANCESCA GAIA
 Distribuzione geografica
Continente #
EU - Europa 3.602
NA - Nord America 1.987
AS - Asia 1.783
SA - Sud America 214
AF - Africa 36
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.634
Nazione #
US - Stati Uniti d'America 1.911
DE - Germania 1.447
GB - Regno Unito 836
CN - Cina 630
SG - Singapore 485
IT - Italia 337
SE - Svezia 243
RU - Federazione Russa 184
FI - Finlandia 157
BR - Brasile 155
HK - Hong Kong 151
TR - Turchia 115
FR - Francia 108
IN - India 97
NL - Olanda 93
VN - Vietnam 91
UA - Ucraina 71
KR - Corea 64
CA - Canada 57
BD - Bangladesh 54
EU - Europa 54
IE - Irlanda 49
CO - Colombia 31
JP - Giappone 23
CI - Costa d'Avorio 17
ID - Indonesia 16
ES - Italia 14
MX - Messico 14
AR - Argentina 11
PL - Polonia 10
AU - Australia 8
GR - Grecia 8
ZA - Sudafrica 8
IQ - Iraq 7
CZ - Repubblica Ceca 6
IL - Israele 6
CH - Svizzera 5
DK - Danimarca 5
PH - Filippine 5
RO - Romania 5
UY - Uruguay 5
UZ - Uzbekistan 5
BE - Belgio 4
JO - Giordania 4
PK - Pakistan 4
PT - Portogallo 4
TW - Taiwan 4
EC - Ecuador 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
AL - Albania 2
BG - Bulgaria 2
BO - Bolivia 2
CL - Cile 2
HR - Croazia 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AT - Austria 1
AZ - Azerbaigian 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
EG - Egitto 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NO - Norvegia 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
SN - Senegal 1
SO - Somalia 1
VE - Venezuela 1
Totale 7.687
Città #
Frankfurt am Main 898
Southend 767
Singapore 261
Munich 194
Ashburn 186
Beijing 166
Chandler 140
Hong Kong 140
Milan 125
Helsinki 112
San Jose 111
Seattle 108
Princeton 80
Dallas 79
Wilmington 78
Fairfield 71
Mountain View 51
Dublin 49
Jacksonville 45
Council Bluffs 42
Somerville 42
Dearborn 40
Hefei 40
Bengaluru 39
Redmond 39
Los Angeles 38
Santa Clara 38
Toronto 37
Nanjing 36
Lauterbourg 34
Grafing 31
Ho Chi Minh City 30
New York 29
Bogotá 28
Sakarya 28
Woodbridge 28
Moscow 27
Andover 26
Buffalo 25
Hanoi 25
Shanghai 25
Berlin 24
Boardman 24
Serra 24
Columbus 20
Guangzhou 20
Houston 20
Abidjan 17
Istanbul 17
The Dalles 17
Des Moines 14
Hamburg 13
Rome 13
Jinan 12
Nürnberg 12
Phoenix 12
Shenyang 12
Cangzhou 11
Eitensheim 11
Odernheim 11
Tokyo 11
Cambridge 10
Changsha 10
Jyväskylä 10
Redwood City 10
São Paulo 10
Falls Church 9
Hangzhou 9
Jakarta 9
Kiez 9
Tianjin 9
Chicago 8
Düsseldorf 8
Hanover 8
Kunming 8
Mumbai 8
Nanchang 8
Turin 8
Ann Arbor 7
Athens 7
Atlanta 7
Bitonto 7
Hebei 7
London 7
Naples 7
Rio de Janeiro 7
San Diego 7
San Francisco 7
Zhengzhou 7
Bologna 6
Chongqing 6
Foshan 6
Hyderabad 6
Orem 6
Pisa 6
Roxbury 6
Shenzhen 6
Ankara 5
Fuzhou 5
Montevideo 5
Totale 4.994
Nome #
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571 454
Upfront treatment of mantle cell lymphoma by sequential high dose immunochemotherapy supported by in vivo-purged stem cell double autologous transplantation : a single institution experience 394
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. 355
Prognostic scoring system for IGG and IGA monoclonal gammopathies of undetermined significance 347
Frontline antiviral therapy in a series of HCV-related low grade non-Hodgkin lymphoma 346
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) 336
Fludarabine, cyclophosphamide and rituximab in patients with advanced untreated indolent B-cell non-follicular lymphomas : final result of phase two study of Fondazione Italiana Linfomi (FIL) 314
Post-transplant lymphoproliferative disorders in liver and kidney recipients : a single institution experience 311
Indolent B-cell lymphomas treated upfront with antiviral therapy : a series of 13 patients 305
Retrospective analysis of salvage regimen for relapsed or refractory classical Hodgkin lymphoma 266
Diagnostic Role of Flow Cytometry Analysis of Bioptical Samples in the Diagnosis of Lymphoid Tumors 255
Frontline treatment with the combination fludarabine-cyclophosphamide in low-grade non-follicular non-Hodgkin lymphoma : a long term updating of GISL LL02 trial 247
Role of positron emission tomography in indolent non Hodgkin lymphomas 231
The investigation of genomic profiles in primary plasma cell leukemias by means of an integrative microarray approach 229
Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decade 217
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias 212
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance 208
IgG and IgA Monoclonal Gammopathies of Undetermined Significance (MGUS) at Low Risk of Evolution : Proposal and Validation of a Prognostic Scoring System 202
Front-line treatment of low-grade non-follicular non-hodgkin lymphoma : final report of GISL LL02 trial 198
ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma 187
Treatment with hydroxyurea as single agent does not increase the risk of second malignancies in essential thrombocytopenia patients 178
Natural and assisted conceptions in male cancer recipients of hematopoietic cell transplantation who stored their semen for fertility preservation 172
Febrile Neutropenia Risk Assesment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens 169
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 159
Final report 50F GISL LL02 trials for thr treatment of low-grade non- follicular non- Hodgkin lymphoma, at diagnosis 158
STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation 158
Low risk IgG Monoclonal Gammopathy of undetermined significance (MGUS) : proposal and validation of a prognostic scoring system 151
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of diesease 148
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients 148
Alpha 1 acid glycoprotein (AGP) binds to STI571 and alters its tissue distribution and intracellular concentrations 141
Second malignancies in essential thrombocytosis : a retrospective analysis of 331 patients from a single institution 140
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 136
Differences between In Vivo and In Vitro Sensitivity to Imatinib of Bcr/Abl+ Cells Obteined from Leukemic Patients 136
Wait and see: a case of EBV + cutaneous extranodal NK/T-type lymphoma with indolent behaviour 118
Sex determination and differentiation in Asparagus officinalis L 108
Normalization of duodenal mucosa after treatment with Janus kinase (JAK) inhibitor in refractory celiac disease type 2 66
Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients 57
Transient Bacillary Layer Detachment During the Disease Course of Primary Vitreoretinal Lymphoma 8
null 3
Totale 7.968
Categoria #
all - tutte 17.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.883


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202131 0 0 0 0 0 0 0 0 0 0 0 31
2021/2022394 45 9 15 9 28 36 41 21 84 25 28 53
2022/2023526 64 54 49 49 67 97 10 23 64 3 28 18
2023/2024863 16 28 18 29 61 47 120 112 54 117 129 132
2024/20251.377 116 130 100 142 52 74 119 129 117 123 69 206
2025/20261.797 200 156 200 168 162 108 156 136 157 156 157 41
Totale 7.968